Company Focus
Accord Healthcare
Latest Accord Healthcare News
Generics
Paul Burden has been appointed associate vice president and country head of Accord UK, effective immediately. 5 January 2026
Related News
Insights
Company Spotlight
A biotechnology company, based in China, developing car-t-based therapeutics for haematological and metabolic and endocrine diseases with a focus on addressing unmet medical need.
Latest News & Features of interest to Accord Healthcare
Generics
Paul Burden has been appointed associate vice president and country head of Accord UK, effective immediately. 5 January 2026
Pharmaceutical
As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, the company’s new office in Stockley Park, London, is as impressive as it gets. 11 December 2025
Pharmaceutical
The European Medicines Agency’s EMA’s human medicines committee (CHMP) recommended seven novel medicines for approval at its November 2025 meeting. 15 November 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated, and has spread within the lungs or to other parts of the body. 21 June 2025
Pharmaceutical
The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three biosimilars for approval at its March 2025 meeting. 28 March 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its February 2025 meeting. The European Commission is expected to announce a final decision on approval in the coming months. 1 March 2025
Biotechnology
The European Commission has approved Hetronifly (serplulimab) in combination with carboplatin and etoposide as a first-line treatment for extensive-stage small cell lung cancer. 6 February 2025
Biosimilars
Accord BioPharma, a specialty division of Intas Pharmaceuticals, has entered into an agreement to acquire Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) business. 4 December 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biosimilars
The fully-owned Intas Pharmaceuticals subsidiary Accord Healthcare has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for Imuldosa. 21 October 2024
Latest In Brief for Accord Healthcare
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze